Abstract
There is considerable interest in designing an effective vaccine to the ubiquitous Epstein-Barr virus (EBV). An important role for EBV-specific cytotoxic T lymphocytes (CTLs) in eliminating virus-infected cells is well established. Limited studies using a small number of immune donors have defined target epitopes within the latent antigens of EBV. The present study provides an extensive analysis of the distribution of class I-restricted CTL epitopes within EBV-encoded proteins. Using recombinant vaccinia encoding individual EBV latent antigens (Epstein-Barr nuclear antigen [EBNA] 1, 2, 3A, 3B, 3C, LP, and LMP 1), we have successfully localized target epitopes recognized by CTL clones from a panel of 14 EBV-immune donors. Of the 20 CTL epitopes localized, five were defined at the peptide level. Although CTL clones specific for nine epitopes recognized both type 1 and type 2 transformants, a significant number of epitopes (7/16 epitopes for which EBV type specificity was determined) were detected only on type 1 EBV transformants. Vaccinia recombinants encoding EBNA 3A and EBNA 3C were recognized more frequently than any other vaccinia recombinants used in this study, while no CTL epitopes were localized in EBNA 1. Surprisingly, epitope specificity for a large number of EBV-specific CTL clones could not be localized, although vaccinia recombinants used in this study encoded most of the latent antigens of EBV. These results suggest that any EBV vaccine based on CTL epitopes designed to provide widespread protection will need to include not only latent antigen sequences but also other regions of the genome. The apparent inability of human CTLs to recognize EBNA 1 as a target antigen, often the only latent antigen expressed in Burkitt's lymphoma and nasopharyngeal carcinoma, suggests that EBV-specific CTL control of these tumors will not be feasible unless the down-regulation of latent antigens can be reversed.
MeSH Terms
Amino Acid Sequence
Antigens, Viral/immunology
Epitopes/analysis
Epstein-Barr Virus Nuclear Antigens
Herpesvirus 4, Human/immunology
Histocompatibility Antigens Class I/immunology
Humans
Immunization
Molecular Sequence Data
Recombination, Genetic
T-Lymphocytes, Cytotoxic/immunology
Vaccines, Synthetic/immunology
Vaccinia virus/genetics
Viral Vaccines/immunology
Chemicals
Antigens, Viral
Epitopes
Epstein-Barr Virus Nuclear Antigens
Histocompatibility Antigens Class I
Vaccines, Synthetic
Viral Vaccines
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Khanna R
Queensland Institute of Medical Research, Bancroft Centre, Brisbane, Australia.
Burrows S R
Kurilla M G
Jacob C A
Misko I S
Sculley T B
Kieff E
Moss D J
References (26)
26 references, click to expand
-
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.
Int J Cancer. 1978 Dec;22(6):662-8
PMID: 214405
-
Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.
Science. 1984 Jun 29;224(4656):1431-3
PMID: 6427925
-
The specificity of recognition of a cytotoxic T lymphocyte epitope.
Eur J Immunol. 1992 Jan;22(1):191-5
PMID: 1370414
-
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease.
Lancet. 1991 Feb 9;337(8737):320-2
PMID: 1671232
-
An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).
J Exp Med. 1990 Jan 1;171(1):345-9
PMID: 1688611
-
An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.
J Virol. 1990 Aug;64(8):3974-6
PMID: 1695259
-
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.
Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9478-82
PMID: 1719531
-
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.
Nature. 1991 Dec 12;354(6353):453-9
PMID: 1721107
-
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.
Immunology. 1991 Nov;74(3):504-10
PMID: 1722774
-
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
Proc Natl Acad Sci U S A. 1990 Apr;87(8):2906-10
PMID: 2158098
-
General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.
Proc Natl Acad Sci U S A. 1985 Aug;82(15):5131-5
PMID: 2410914
-
T-cell antigenic sites tend to be amphipathic structures.
Proc Natl Acad Sci U S A. 1985 Oct;82(20):7048-52
PMID: 2413457
-
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.
Cell. 1986 Mar 28;44(6):959-68
PMID: 2420472
-
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.
Virology. 1989 Aug;171(2):401-8
PMID: 2548326
-
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.
EMBO J. 1987 Sep;6(9):2743-51
PMID: 2824192
-
Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.
Nature. 1988 Feb 25;331(6158):719-21
PMID: 2830541
-
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
J Exp Med. 1988 Jun 1;167(6):1811-24
PMID: 2898508
-
Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
Nature. 1985 Oct 17-23;317(6038):629-31
PMID: 2997615
-
Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
IARC Sci Publ. 1985;(60):249-64
PMID: 2998992
-
An improved rosetting assay for detection of human T lymphocytes.
J Immunol Methods. 1974 Jul;5(2):131-5
PMID: 4600315
-
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.
Cell Immunol. 1984 Sep;87(2):646-58
PMID: 6088089
-
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.
Proc Natl Acad Sci U S A. 1984 Dec;81(23):7632-6
PMID: 6209719
-
Long-term T-cell-mediated immunity to Epstein-Barr virus.
Cancer Res. 1981 Nov;41(11 Pt 1):4216-21
PMID: 6272965
-
HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies.
Int J Cancer. 1984 Feb 15;33(2):239-43
PMID: 6319303
-
Biological activity of recombinant human interleukin-2 produced in Escherichia coli.
Science. 1984 Mar 30;223(4643):1412-4
PMID: 6367046
-
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
J Exp Med. 1992 Jul 1;176(1):157-68
PMID: 1319456